The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
Phones:
+7 (495) 482-4118
+7 (495) 482-4329
  • Toll-free number for subscriptions:
    +8 800 250-18-12
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kozlova I.V.

FGBU "NII glaznykh bolezneĭ" RAMN, Moskva

Myalina Yu.N.

V.I. Razumovsky Saratov State Medical University, Ministry of Health of Russia, Saratov, Russia

Lipina L.P.

OOO “Leyla Roz” Clinic, Moscow, Russia

Bakulev A.L.

Clinic of Dermal and Venereal Diseases Saratov State Medical University

Optimization of therapy for hepatobiliary disorders in psoriatic patients

Authors:

Kozlova I.V., Myalina Yu.N., Lipina L.P., Bakulev A.L.

More about the authors

Journal: Therapeutic Archive. 2017;89(12): 204‑210

DOI: 10.17116/terarkh20178912204-210

Read: 7750 times

Contact the author
Table of contents

OPTIMIZATION OF THERAPY FOR HEPATOBILIARY DISORDERS IN PSORIATIC PATIENTS
OPTIMIZATION OF THERAPY FOR HEPATOBILIARY DISORDERS IN PSORIATIC PATIENTS

To cite this article:

Kozlova IV, Myalina YuN, Lipina LP, Bakulev AL. Optimization of therapy for hepatobiliary disorders in psoriatic patients. Therapeutic Archive. 2017;89(12):204‑210. (In Russ.)
https://doi.org/10.17116/terarkh20178912204-210

МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Sarcopenia index for dete­cting of the decreased muscle stre­ngth and mass in patients with the non-alcoholic fatty liver disease. Russian Journal of Preventive Medi­cine. 2025;(7):68-74
Non-alcoholic fatty liver disease: a view formation on the problem and its significance for the clinical practice. Russian Journal of Preventive Medi­cine. 2025;(7):127-132
Psychodermatological aspe­cts of psoriasis, current condition of problem. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(4):403-411
New approach to clinical evaluation of nail lesions in psoriasis. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(4):453-460
Persistence of skin process remi­ssion in patients with mode­rate and severe psoriasis vulgaris in application of neta­kimab: a five-year obse­rvational study resu­lts. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(4):462-468
Combination of urso­deoxycholic acid and glycyrrhizic acid (Phosphogliv URSO) in the treatment of nona­lcoholic fatty liver disease: resu­lts of a multicenter randomized clinical trial on effi­cacy and safety. Russian Journal of Evidence-Based Gastroenterology. 2025;(3):71-84
Deve­lopment of a predictive model for the identification of patients with high risk of psoriatic arthritis and asse­ssment of the effi­cacy of early treatment with neta­kimab, IL-17A inhi­bitor. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(5):625-634
Unde­restimated itching symptom in psoriasis: diagnostic limi­tations and correction paths. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(5):675-682
Clinical expe­rience of combination glucocorticosteroids use for the treatment of psoriasis and sebo­rrheic dermatitis in adults. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(5):692-697
The effi­cacy of hepa­toprotective agents in the treatment of non-alcoholic fatty liver disease: meta­bolic effe­cts and impact on liver fat content. Russian Journal of Preventive Medi­cine. 2026;(1):86-93
Abstract:

Aim. To optimize management tactics in patients with diseases of the liver and gallbladder in the presence of progressive psoriasis. Subjects and methods. The investigation enrolled 78 patients with nonalcoholic fatty liver disease (NAFLD) and different forms of gallbladder abnormality in the presence of progressive moderate and severe psoriasis. The patients were randomly divided into 2 groups: 1) phosphogliv; 2) ursosan with the main active ingredient ursodeoxycholic acid (UDCA). A prospective follow-up study accompanied by dynamic clinical, laboratory, and instrumental monitoring was carried out for 24 weeks. Clinical, biochemical, and ultrasound studies, including liver elastography, were applied. Results. The use of UDCA (Ursosan 15 mg/kg for 24 weeks) to treat NAFLD and gallbladder abnormality in methotrexate-treated patients with progressive moderate and severe psoriasis contributed to the normalization of hepatic steatosis index, lipid composition, and lithogenic index, to the reduction of biliary sludge, and to the stabilization of liver fibrosis. Improvement in the functional status of the liver and gallbladder has contributed to the achievement of a more complete remission of dermatosis. Conclusion. The effects of UDCA in the therapy of NAFLD and gallbladder abnormality in patients with progressive psoriasis were greater than those of phosphogliv.

Keywords:

psoriasis
non-alcoholic fatty liver disease
hepatic steatosis index
lithogenic index
ursodeoxycholic acid (ursosan)

Authors:

Kozlova I.V.

FGBU "NII glaznykh bolezneĭ" RAMN, Moskva

Myalina Yu.N.

V.I. Razumovsky Saratov State Medical University, Ministry of Health of Russia, Saratov, Russia

Lipina L.P.

OOO “Leyla Roz” Clinic, Moscow, Russia

Bakulev A.L.

Clinic of Dermal and Venereal Diseases Saratov State Medical University

Close metadata

References:

  1. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: A systematic review of incidence and prevalence. J Investig Dermatol. 2013;133:377-385. https://doi.org/10.1038/jid.2012.339
  2. Boehncke WH, Schön MP. Psoriasis. Lancet. 015;386(9997):983-994. https://doi.org/10.1016/S0140-6736(14)61909-7
  3. Griffiths CE, Barker JN Pathogenesis and clinical features of psoriasis. Lancet. 2007;370:263-271. https://doi.org/10.1016/S0140-6736(07)61128-3
  4. Bakulev AL, Shagova YuV, Kozlova IV. Psoriasis as system pathology. Saratovskii nauchno-meditsinskii zhurnal. 2008;1:13-19. (In Russ.)
  5. Gottlieb AB, Chao C, Dann F. Psoriasis comorbidities. J Dermatol Treat. 2008;19:5-21. https://doi.org/10.1080/09546630701364768
  6. Jamnitski A, Symmons D, Peters MJ, Sattar N, McInnes I, Nurmohamed MT. Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review. Ann Rheum Dis. 2014;72(2):211-216. https://doi.org/10.1136/annrheumdis-2011-201194
  7. Rozumbaeva LP, Kozlova IV, Byikova AP. Comorbidity of diseases of the liver, biliary tract and psoriasis. Eksperimental’naja i klinicheskaja gastrojenterologija. 2015;114(2): 24-28. (In Russ.)
  8. Ni C, Chiu MW. Psoriasis and comorbilities: links and risks. Clin Cosmet Investig Dermatol. 2014;7:199-132. https://doi.org/10.2147/CCID.S44843
  9. Candia R, Ruiz A, Torres-Robles R, Chavez-Tapia N, Mendez-Sanchez N, Arrese M. Risk of non-alcoholic fatty liver disease in patients with psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2015;29:656-662. https://doi.org/10.1111/jdv.12847
  10. Rakhimova OYu, Vinogradov YuA, Yurkov MYu, Savitsky AV, Mitrofanova IYu. Crohn disease and psoriasis. Klinicheskaya meditsina. 2008;7:70-72. (In Russ.)
  11. Shagova YuV, Kozlova IV, Bakulev AL. Intestinal pathology in psoriasis. Dal’nevostochnyj vestnik dermatovenerologii, dermatokosmetologii i seksopatologii. 2009;2(5):23-24. (In Russ.)
  12. Augustin M, Radtke MA. Quality of life in psoriasis patients. Expert Rev Pharmacoecon Outcomes Res. 2014;14:559-568. https://doi.org/10.1586/14737167.2014.914437
  13. Mansouri B, Patel M, Menter A. Biological therapies for psoriasis. Expert Opin Biol Ther. 2013;13:1715-1730. https://doi.org/10.1517/14712598.2013.853739
  14. Chládek J, Simková M, Vanecková J, Hroch M, Vávrová J, Hůlek P. Assessment of methotrexate hepatotoxicity in psoriasis patients: a prospective evaluation of four serum fibrosis markers. J Eur Acad Dermatol Venereol. 2013;27(8):1007-1014. https://doi.org/10.1111/j.1468-3083.2012.04643.x
  15. Tan KW, Griffiths CE. Novel systemic therapies for the treatment of psoriasis. Expert Opin Pharmacother. 2016;17:79-92. https://doi.org/10.1517/14656566.2016.1109636
  16. Kotel’nikova AB, Frolova OI, Rayeva TV, Ishutina NP. Clinical and metabolic efficacy of Heptral Ademetionine) in psoriatic patients with a pathology of the hepatobiliary system. Vestnik dermatologii i venerologii. 2009;5:103-111. (In Russ.)
  17. Orlov YeV, Konnov PYe, Kotelnikova YeV. Assessment of the clinical efficacy of the administration of Phosphogliv in complex treatment of psoriasis patients. Vestnik dermatologii i venerologii.2010;4:69-72. (In Russ.)
  18. Musso G, Cassader M, Rosina F, Gambino R. Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials. Diabetologia. 2012;55:885-904. https://doi.org/10.1007/s00125-011-2446-4
  19. Mayev IV, Kucheryavyy YuA, Morozov SV, Saidullaeva MG, Akhtaeva ML, Stukova NYu, Krasnyakova EA. The impact of the ursodeoxycholic acid as monotherapy and in the combination with the lactulose on the biochemical blood tests values of the nonalcoholic steatohepatitis patients. Rossijskij zhurnal gastrojenterologii, gepatologii, koloproktologii. 2013;1:37-51. (In Russ.)
  20. Braga MF, Grace MG, Lenis J, Kennedy FP, Teplinsky AL, Roederer G, Palumbo PJ, Colin P, Leiter LA. Efficacy and safety of ursodeoxycholic acid in primary, type IIa or IIb hypercholesterolemia: a multicenter, randomized, double-blind clinical trial. Atherosclerosi. 2009;203(2):479-482. https://doi.org/10.1016/j.atherosclerosis.2008.08.001
  21. La Brecque DR, Abbas Z, Anania F, Ferenci P, Khan AG, Goh KL, Hamid SS, Isakov V, Lizarzabal M. World Gastroenterology Organisation global guidelines: nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Clin Gastroenterol. 2014;48:467-473. https://doi.org/10.1097/MCG.0000000000000116
  22. Ivashkin VT, Maev IV, Baranskaja EK, Ohlobystin AV, Shul’pekova JuO, Truhmanov AS, Sheptulin AA, Lapina TL, Ivashkin VT, Maev IV, Baranskaja EK, Ohlobystin AV, Shul’pekova JuO, Truhmanov AS, Sheptulin AA, Lapina TL. Gallstone disease diagnosis and treatment: guidelines of the Russian gastroenterological association. Rossijskij zhurnal gastrojenterologii, gepatologii, koloproktologii. 2016;3:64-80. (In Russ.)
  23. Warttig S, Ward S, Rogers G; Guideline Development Group. Diagnosis and management of gallstone disease: summary of NICE guidance. BMJ. 2014;349:g6241. https://doi.org/10.1136/bmj.g6241
  24. Bakulev AL, Znamenskaja LF, Hobejsh MM, Olisova OJu Federal’nye klinicheskie rekomendacii po vedeniju bol’nyh psoriazom. M., 2013. (In Russ.)
  25. Nast A, Gisondi P, Ormerod AD, Saiag P, Smith C, Spuls PI, Arenberger P, Bachelez H, Barker J, Dauden E, de Jong EM, Feist E, Jacobs A, Jobling R, Kemény L, Maccarone M, Mrowietz U, Papp KA, Paul C, Reich K, Rosumeck S, Talme T, Thio HB, van de Kerkhof P, Werner RN, Yawalkar N. European S3-Guidelines on the systemic treatment of psoriasis vulgaris — Update 2015 — Short version — EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2015;29(12):2277-2294. https://doi.org/10.1111/jdv.13354
  26. Il’chenko AA. Bolezni zhelchnogo puzyrja i zhelchnyh putej: Rukovodstvo dlja vrachej. M., 2011. (In Russ.)
  27. Lee JH, Kim D, Kim HJ, Lee CH, Yang JI, Kim W, Kim YJ, Yoon JH, Cho SH, Sung MW, Lee HS. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010;42(7):503-508. https://doi.org/10.1016/j.dld.2009.08.002
  28. Jushhuk ND, Znojko OO, Safiullina NH. Biopsy of liver and possibility of the not invasion monitoring of fibrosis at chronic viral hepatitis of С. Klinicheskie perspektivy gastrojenterologii, gepatologii. 2002;1:9-16. (In Russ.)
  29. Patel K, Lajoie A, Heaton S, Pianko S, Behling CA, Bylund D, Pockros PJ, Blatt LM, Conrad A, McHutchison JG. Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C. J Gastroenterol Hepatol. 2003; 18(3):253-257. https://doi.org/10.1046/j.1440-1746.2003.02930.x
  30. Shenoy C, Shenoy MM, Rao GK. Dyslipidemia in Dermatological Disorders. N Am J Med Sci. 2015;7(10):421-428. https://doi.org/10.4103/1947-2714.168657
  31. Kopytova TV, Abalikhina EP, Shchelchkova NA. Significance of determination of lipids in biological substrates for evaluation of metabolic processes in psoriasis. Klinicheskaya laboratornaya diagnostika. 2007;11:20-23. (In Russ.)
  32. Akhlupkina MV, Svistunov AA, Bakulev AL. The significance of laboratory indicators in the assessment of effectiveness of implementation of essential) phospholipides in case of psoriasis. Klinicheskaya laboratornaya diagnostika. 2011;1:36. (In Russ.)
  33. Abedini R, Salehi M, Lajevardi V, Beygi S. Patients with psoriasis are at a higher risk of developing nonalcoholic fatty liver disease. Clin Exp Dermatol. 2015;40:722-727. https://doi.org/10.1111/ced.12672
  34. Hardwick RN, Clarke JD, Lake AD, Canet MJ, Anumol T, Street SM, Merrell MD, Goedken MJ, Snyder SA, Cherrington NJ. Increased susceptibility to methotrexate-induced toxicity in nonalcoholic steatohepatitis. Toxicol Sci. 2014;142:45-55. https://doi.org/10.1093/toxsci/kfu156
  35. Lindsay K, Fraser AD, Layton A, Goodfield M, Gruss H, Gough A. Liver fibrosis in patients with psoriasis and psoriatic arthritis onlong-termhighcumulative dose methotrexate therapy. Rheumatology. 2009;48:569-572. https://doi.org/10.1093/rheumatology/kep023
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.